Form 4: Eli Lilly SVP Sells 1,000 Shares in Planned Transaction

Eli Lilly's SVP of Finance and CAO, Donald A. Zakrowski, sold 1,000 shares of common stock for over $1 million as part of a pre-arranged trading plan.

Summary

• Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly & Co., sold 1,000 shares of common stock.
• The transaction occurred on November 13, 2025, at a price of $1,010.5 per share, totaling $1,010,500.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 20, 2024.
• Following the transaction, Mr. Zakrowski directly owns 2,839.659 shares and indirectly owns 1,727.9 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns, suggesting a planned financial move rather than a reaction to adverse company-specific news.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned diversification or liquidity event rather than a reaction to new, negative information.

Negatives

• An insider sale, even if planned, reduces the direct ownership stake of a senior executive in the company.

Industry Context

This insider transaction is a routine disclosure for a senior executive at a major pharmaceutical company like Eli Lilly. Such planned sales are common for executives managing personal finances and diversifying portfolios, and do not inherently reflect on the company's operational performance or industry trends.

Related Party Transactions

• Donald A. Zakrowski, a Senior Vice President, Finance, and Chief Accounting Officer of Eli Lilly & Co., sold 1,000 shares of the company's common stock.

Stakeholder Impact

• Shareholders may note the reduction in direct ownership by a senior executive, though the pre-planned nature of the sale under a 10b5-1 plan typically lessens concerns about management's confidence in the company's future.

Key Dates

Recommendation

The filing details a pre-planned insider stock sale by a senior executive, which is a routine event for personal financial management and diversification. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific transaction.

Keywords

Eli Lilly, LLY, Insider Trading, Form 4, Stock Sale, Donald A. Zakrowski, 10b5-1 Plan, Executive Compensation, Pharmaceuticals